Globus Medical Inc A (GMED) Earnings: Strong Q2 Performance and Reaffirmed FY Revenue Forecast.

Globus Medical Inc A on Smartkarma

Analyst coverage of Globus Medical Inc A on Smartkarma by Baptista Research highlights both positive and challenging aspects of the company’s performance. In their report titled “Globus Medical’s $250M Nevro Bet: Can This Bold Acquisition Disrupt Neuromodulation?“, the analysts noted a mixed performance in the first quarter of 2025. Despite a slight decline in revenue attributed to softer sales in enabling technology and supply chain disruptions, Globus Medical reported $598 million in revenue. This analysis points to both strengths and challenges for the company.

Furthermore, Baptista Research‘s report “Globus Medical: Nevro Acquisition & Market Expansion Driving Our ‘Outperform’ Rating!” reflects a bullish sentiment towards Globus Medical. The company closed 2024 on a positive note, achieving a record high revenue of $2.519 billion, signifying a remarkable 61% increase over the previous year. Additionally, the increase in non-GAAP EPS to $3.04, despite a 20% expansion in diluted shares, showcases strong financial growth. This positive performance, driven by the Nevro acquisition and market expansion, has contributed to Baptista Research‘s ‘Outperform’ rating for Globus Medical Inc A.

A look at Globus Medical Inc A Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, the long-term outlook for Globus Medical Inc A appears to be positive. The company scores well in resilience, growth, and value factors, indicating a solid foundation for future growth potential. With a focus on promoting healing in patients with spine disorders, Globus Medical Inc A is positioned to benefit from the ongoing demand for medical devices in this specialized market.

Globus Medical Inc A‘s commitment to innovative fusion and disruptive technologies sets it apart in the medical device industry. While the company may have lower scores in dividend and momentum, its strengths in value, growth, and resilience suggest a promising trajectory for long-term investors seeking exposure to the healthcare sector.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma